Afleveringen
-
In this June series of the podcast, we focus on JAK inhibitors. This episode kicks off with a detailed review of an Italian study published in Expert Opinion in Drug Safety, which examines the incidence and management of infections in patients with alopecia areata treated with JAK inhibitors. Dr. Donovan discusses the findings, emphasizing that about one in three patients on JAK inhibitors may develop infections, highlighting the need for careful monitoring and potential treatment pauses.
Additionally, Dr. Donovan reviews a study from New York in Archives of Dermatologic Research, which reveals low vaccination rates among patients with immune-mediated diseases on biologics and JAK inhibitors. The study underscores the importance of pre-treatment vaccinations to mitigate infection risks.
Join us next week as we explore the efficacy and cost benefits of generic tofacitinib in managing alopecia areata, part of our ongoing series on JAK inhibitors. Stay tuned for more insights and expert analysis on the Evidence-Based Hair Podcast.
STUDIES REFERENCE IN THIS WEEK'S EPISODE
Giacomo Caldarola et al. Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment. Expert Opin Drug Saf. 2024 May 8:1-5.
Hren MG and Khattri S. Low rates of vaccination among atopic dermatitis, alopecia areata, psoriasis, and psoriatic arthritis patients on biologics. Arch Dermatol Res. 2024 May 25;316(6):285
-
In this episode, Dr. Jeff Donovan, a dermatologist and hair loss specialist, examines the effect of topical minoxidil in enhancing beard hair growth in men
Dr. Donovan focuses on a study published in Sage Open Medicine Case Reports titled, "Facial Hair Enhancement with Minoxidil and Off-Label Use". This study highlights the impact of using topical minoxidil for beard hair growth. As a subject frequently questioned by men worldwide, understanding the benefits, side effects, and the result of its use is vital.
A noteworthy part of this study was that it compared the use of topical minoxidil by two identical twins. Only one of the twins applied minoxidil on his face, and as early as the first month, finer, lighter-colored hairs appeared on his beard and mustache. He experienced hair shedding for a few months but still showed overall improvement in hair density and count after using minoxidil for 16 months.
Despite mild side effects such as skin dryness and hypertrichosis on ears and forehead, as well as increased body hair in other areas, the study shows that minoxidil can be an effective strategy for males wishing to enhance their facial hair. The patient in the case report switched to topical minoxidil foam due to dry flakiness caused by the solution, suggesting that the foam might be a preferable choice for some users.
To sum up, this 16-month-long study provides valuable insights on the potential effectiveness of using minoxidil for beard growth. Despite the side effects and need for more long-term data, the results suggest that it is a reasonably safe and potentially helpful approach for those who desire to improve their facial hair density.
-
Zijn er afleveringen die ontbreken?
-
In this episode, we will dive into fascinating recent studies about the side effects of Minoxidil, a widely-known medication for hair loss treatment.
This podcast highlights new research regarding what Dr. Donovan calls "the OMAHA effect" (ORAL MINOXIDIL ALCOHOL HANGOVER ASSOCIATION), the surprising association between oral minoxidil use and exacerbated alcohol hangover symptoms. This phenomenon challenges previous conceptions in the medical field and warrants further investigation into potential implications for patients using oral Minoxidil.
However, though intriguing, the data about the OMAHA effect lacks detailed and quantitative information about the patients involved and their experiences. This calls for more precise and extensive research on the matter. Dr. Donovan emphasizes the need to gather more information before this knowledge can lead to changes in medical practice.
Moving forward, the episode also examines another study analyzing the association between topical Minoxidil and hair discoloration. This study equips you with more concrete data, reporting that about one-fourth of patients using Minoxidil perceive that the treatment has led to their hair graying. Despite the product monograph advising patients to stop minoxidil use when hair discoloration is noticed, the podcast argues that this abrupt termination might not be practical as patients risk losing the new hair growth achieved with Minoxidil when they stop the treatment.
Overall, this discussion underscores how hair graying and discoloration, like hair loss, also significantly impacts individuals' lives. As researchers dedicate more attention to understanding these issues, expect more practical guidelines and breakthroughs in combatting them.
Join Dr. Donovan every week for insightful discussions about ground-breaking studies relevant to hair loss and its treatment. Stay tuned for our next episode where we look into topical Minoxidil use for beard growth.
-
In this episode, we dive into a thought-provoking study by Sanfilippo and Friedman, "Survey of Dermatology Practitioners' Opinions and Prescribing Habits of Oral Minoxidil for the Treatment of Androgenetic Hair Loss".
The study provides valuable insights into the perceptions of practitioners on oral minoxidil, an increasingly popular option for treating hair loss.
We discuss the results of this survey and compare it with previous studies, shedding light not only on the effectiveness of oral minoxidil but also on the practitioners' comfort level in prescribing it and patients' satisfaction with its results.
The pulse of the global community and the evidence provided by well-conducted studies play a significant role in shaping our understanding of oral minoxidil. There's a critical need for long-term evaluations and more comprehensive studies to establish its effects and side effects over years of use.
Stay tuned for more in-depth discussions as we continue to explore the realm of hair loss treatments.
And don't forget, if you want to immerse yourself in the study of hair loss and acquire advanced clinical and problem-solving skills, consider applying for a training position in the Evidence-Based Hair Fellowship, the world's most comprehensive program for physicians and allied health professionals.
-
In this episode of the Evidence-Based Hair Podcast hair loss specialist Dr. Jeff Donovan breaks down the findings of a recent study comparing oral minoxidil and topical minoxidil in the treatment of male androgenetic alopecia. Published in JAMA Dermatology, the study challenged popular opinions by revealing similar performance between the two types of minoxidil, putting a spotlight on the importance of robust evidence from randomized controlled trials.
Interestingly, Dr. Donovan examined the historical usage of oral minoxidil, once a blood pressure medication, in treating hair loss and the subsequent need for more rigorous studies to solidify its effectiveness. The episode also covers the surprising conclusion that oral minoxidil did not significantly outperform its topical counterpart, contrary to what the mainstream assumes.
Diving deeper into the debate, Dr. Donovan explored differing perspectives derived from the Pantchprateep et al and Penha et al studies of oral minoxidil. Where the Panchaprateep et al study suggested that all patients saw some improvement, the Penha et al study showed that not all participants experienced the same positive results.
In an in-depth examination of the 'Oral Minoxidil versus Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial', the potential side effects, including minor adverse effects of both treatments were also discussed. While not definitive in recommending one treatment over the other, the episode sparks stimulating discussions around the efficacy of oral minoxidil, its comparison to topical minoxidil, and the potential of randomized controlled trials in determining the optimal treatment for male androgenetic hair loss.
STUDIES REVIEWED IN THIS EPISODE
Penha MA et al. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatol . 2024 Apr 10:e240284. doi: 10.1001/jamadermatol.2024.0284. Online ahead of print
Panchaprateep et al. Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment. Dermatol Ther. 2020 Dec;10(6):1345-1357
-
This episode is dedicated to a fascinating subject – drug-induced alopecia areata. In addition to genetic factors, alopecia areata is also influenced by environmental factors such as infections and medications. In this episode, Dr Donovan highlights two studies: “A Cross-Sectional Analysis of Medications Used by Patients Reporting Alopecia Areata on the FDA Adverse Events Reporting System” by Ravapati et al and “Drug-Induced Alopecia Areata: A Systematic Review” by Ezemma et al. These studies present an intensive exploration of drugs possibly causing alopecia areata.
Studies show that monoclonal antibodies are common culprits, and reports of drug-induced alopecia areata are rising every over time.
Surprisingly, it has been observed that the onset of drug-induced alopecia areata could be delayed by as much as a year. Also, patients who discontinued the alleged drug stimulating alopecia areata experienced regrowth of hair, while those who didn't, failed unless treated.
Email is [email protected] or visit our website www.donovanhairacademy.com.
Thank you all for joining. See you next week!
-
Welcome to a new episode of the Evidence-Based Hair Podcast, where we discuss some questions surrounding the relationship between dupilumab and lymphoma. This episode dives deep into a study by Hasan and colleagues that explores the fascinating and somewhat controversial relationship between Dupilumab, a drug often used to treat atopic dermatitis patients with alopecia areata, and an increased risk of Cutaneous T-Cell Lymphoma (CTCL). Despite its potential benefits, does Dupilumab truly cause CTCL, or does it simply unmask the disease in patients who were previously misdiagnosed?
Using information from a vast database, authors examined whether patients using dupilumab showed an increased incidence of CTCL compared to those who did not. Findings suggest that users of the drug have a four-fold increased risk of CTCL.
While uncertainties remain on whether Dupilumab triggers lymphomas, causes benign lymphoid reactions, or accelerates existing CTCL, this episode underscores the drug's potential risks and the importance of careful diagnostics before prescribing it.
As we continue to gather data and debate the varying viewpoints, we invite you to join us in disentangling the complex relationship between Dupilumab and CTCL. Stay tuned for our next episode, where we explore drug-induced alopecia areata and the potential triggering effects of new monoclonal antibodies.
donovanmedical Edited•Season 7 of the Evidence Based Hair Podcast has started. This week I review several fascinating studies: The podcast can be accessed wherever you listen to your podcasts or via the DonovanMedical youtube channel.REFERENCES IN THIS EPISODE Hasan I et al. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study. J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00566-8. doi: 10.1016/j.jaad.2024.03.039. Online ahead of print.Jfri A et al. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review. J Am Acad Dermatol . 2023 May;88(5):1164-1166. doi: 10.1016/j.jaad.2022.12.001. Epub 2022 Dec 5.Espinosa ML et al. Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients. J Am Acad Dermatol . 2020 Jul;83(1):197-199. doi: 10.1016/j.jaad.2020.03.050. Epub 2020 Mar 27. -
This is a recording from the live webinar was conducted live December 13, 2023. This is an annual event that is held every year in mid-December celebrating the top hair research studies.
DERMATOPATHOLOGY
Douglas A et al. Scalp Biopsy Influences Diagnostic Accuracy and Treatment in Black Women with Alopecia: A Retrospective Study. J Am Acad Dermatol. 2023 Jan 31;S0190-9622(23)00157-3.
ANDROGENETIC ALOPECIA
Gupta AK et al.The relative efficacy of monotherapy with 5-alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta-analysis study. J Cosmet Dermatol. 2023 Jun 29
Jimenez-Cauhe J et al. Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermosifiliogr. 2023 Aug 29:S0001-7310(23)00679-8.
ALOPECIA AREATA
Gandhi et al.The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata. Dermatol Ther (Heidelb). 2023 Jan;13(1):285-298.
Li SJ et al. Experiencing Workplace Bullying in Patients with Alopecia Areata: A Cross-Sectional Survey Study. Skin Appendage Disord. 2023 Aug;9(4):258-261
Kazmi A et al. Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response. J Am Acad Dermatol. 2023 Apr 4;S0190-9622(23)00532-7.
King B et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023 May 6;401(10387):1518-1529.
George P et al. Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database., Dermatol Ther (Heidelb). 2023 Aug; 13(8): 1733–1746.
Wang C-W et al. Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations. Clin Immunol. 2023 Oct:255:109737.
Chen J et al. The Incidence of Alopecia Areata in a COVID-19- Vaccinated Population: A Single-Center Review. Cureus 2023
TELOGEN EFFLUVIUM
Michelini S et al. Telogen Effluvium in SARS-CoV-2 Infection: histological aspects. J Eur Acad Dermatol Venereol. 2023 Mar 8.
TINEA CAPITIS
Gold, JA et al. Inadequate diagnostic testing and systemic antifungal prescribing for tinea capitis in an observational cohort study of 3.9 million children, United States. J Am Acad Dermatol. 2023 Feb 15;S0190-9622(23)00189-5.
COSMETIC DERMATOLOGY
Landau M et al. Nonscarring alopecia after temporal lifting technique with dermal fillers. JAAD Case Rep. 2023 May 12;37
FOLLICULITIS DECALVANS
Matard B et al. Folliculitis decalvans and dystrophic epidermolysis bullosa: a significant association. Br J Dermatol 2022 Dec;187(6):1026-1028.
DISCOID LUPUS
Fredeau L et al. Risk factors of progression from discoid lupus to severe systemic lupus erythematosus: a registry-based cohort study of 164 patients. J Am Acad Dermatol. 2023 Mar;88(3):551-559.
DISSECTING CELLULITIS
Cajas-Garcia MS et al. Distinct presentations of scalp dissecting cellulitis manifesting with furrows and gyri. J Eur Acad Dermatol Venereol. 2023 Feb 3.
LICHEN PLANOPILARIS Lim SH et al. Prevalence and Incidence of Comorbid Diseases and Mortality Risk Associated with Lichen Planopilaris: A Korean Nationwide Population-Based Study. Clin Exp Dermatol. 2023 Jul 11;llad235
GENERAL SCARRING ALOPECIA
Kim SR et al. Association of Primary Cicatricial Alopecia with Subsequent Cardiovascular Disease. J Invest Dermatol. 2023 Nov 19:S
CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA
Joshi TP et al. Comorbidities in patients with central centrifugal cicatricial alopecia: a case-control study. Int J Dermatol. 2023 Nov 23.
ACNE KELOIDALIS NUCHAE
Lobato-Berezo A et al. Acne keloidalis nuchae: An international multicentric review of 79 patients. J Eur Acad Dermatol Venereol. 2023 Nov 1.
-
STUDIES REFERENCED IN THIS EPISODE
Pastukhova E et al. Alopecia Areata as a Sequela of COVID-19 Vaccination: A Systematic Review J Cutan Med Surg. 2023 Jan-Feb;27(1):64-65.
Wang C-W et al. Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations. Clin Immunol. 2023 Oct:255:109737.
Genco L et al. Alopecia Areata after COVID-19 Vaccines. Skin Appendage Disord. 2023 Mar;9(2):141-143.
-
STUDIES REVIEWED THIS WEEK:
Chang R et al. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine. 2023 Feb;56:101783
Tesch F et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clin Rheumatol. 2023 Oct;42(10):2905-2914.
Lim SG et al. Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19 JAMA Netw Open. 2023 Oct 2;6(10):e2336120.
Pastukhova E et al. Alopecia Areata as a Sequela of COVID-19 Vaccination: A Systematic Review J Cutan Med Surg. 2023 Jan-Feb;27(1):64-65.
STUDIES TO BE REVIEWED NEXT WEEK (PREVIEW)
Wang C-W et al. Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations. Clin Immunol. 2023 Oct:255:109737.
Genco L et al. Alopecia Areata after COVID-19 Vaccines. Skin Appendage Disord. 2023 Mar;9(2):141-143.
-
STUDIES REFERENCED IN THIS EPISODE:
Workman K and Kindred C (starts at 2:10). Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib. JAAD Case Rep. 2023 Jul 28:39:109-111.
Cook M et al (starts at 12:07). Use of low-level light therapy in management of central centrifugal cicatricial alopecia: A case series of four patients. Photodermatol Photoimmunol Photomed. 2023 Aug 23.
-
ARTICLES COVERED THIS WEEK
STUDY 1:
Ong M et al (starts at 5:12). Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study. J Am Acad Dermatol. 2023 Oct 13:S0190-9622(23)02976-6.
Sanabria et al. Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;
Jimenez-Cauhe J et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022 Dec;87(6):e235-e237
STUDY 2:
Imhof R et al (starts at 16:35). Safety and tolerability of low dose oral minoxidil monotherapy in female pattern hair loss: A retrospective review with longitudinal ambulatory blood pressure monitoring. JAAD Int. 2023 Aug 12:13:50-52.
Ramos PM et al. Minoxidil 1 mg versus minoxidil 5 % topical solution for the treatment of female-pattern hair loss: A randomized clinical trial. J Am Acad Dermatol Jan 2020;82(1):252-253.
STUDY 3:
Jimenez-Cauhe J et al (starts at 24:27). Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermosifiliogr. 2023 Aug 29:S0001-7310(23)00679-8.
Vano-Galvan S et al. Safety of low dose oral minoxidil for hair loss: A multicenter study of 1404 patients. JAAD 2021; 84: 1644-51.
Sanabria B et al. Adverse effects of low dose oral minoxidil for
androgenetic alopecia in 435 patients. JAAD 2021; 84: 1175-78.
ARITCLES COVERED NEXT WEEK (PREVIEW)
Cook M et al. Use of low-level light therapy in management of central centrifugal cicatricial alopecia: A case series of four patients. Photodermatol Photoimmunol Photomed. 2023 Aug 23.
Workman K and Kindred C. Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib. JAAD Case Rep. 2023 Jul 28:39:109-111
-
ARTICLES REFERENCED IN THIS EPISODE
Krauss A (starts at 12:44). Why all randomised controlled trials produce biased results. Ann Med. 2018 Jun;50(4):312-322.
Van Noreen R (starts at 15:33). Medicine is plagued by untrustworthy clinical trials. How many studies are faked or flawed? Nature. 2023 Jul;619(7970):454-458. Listen at https://youtu.be/_QLvzCr6nz4?feature=shared
Carlisle JB (starts at 16:28). False individual patient data and zombie randomised controlled trials submitted to Anaesthesia. Anaesthesia. 2021 Apr;76(4):472-479.
PREVIEW STUDIES FOR NEXT WEEK (SEASON 6, EPISODE 3)
Ong M et al. Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study. J Am Acad Dermatol. 2023 Oct 13:S0190-9622(23)02976-6. doi: 10.1016/j.jaad.2023.10.010. Online ahead of print.
Jimenez-Cauhe et al. Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermosifiliogr. 2023 Aug 29:S0001-7310(23)00679-8.
Imhof R et al. Safety and tolerability of low dose oral minoxidil monotherapy in female pattern hair loss: A retrospective review with longitudinal ambulatory blood pressure monitoring. JAAD Int. 2023 Aug 12:13:50-52.
-
Studies Referenced in This Episode: Season 6 Episode 1
King B et al (starts at 4:07). When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. Br J Dermatol. 2023 Sep 14:ljad253.
Gargiulo L et al (starts at 30:22). Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience. J Dermatolog Treat. 2023 Dec;34(1):2268764.
Preview of Studies for New Week: Season 6 Episode 2
Krauss A. Why all randomised controlled trials produce biased results. Ann Med. 2018 Jun;50(4):312-322.
Carlisle JB. False individual patient data and zombie randomised controlled trials submitted to Anaesthesia. Anaesthesia. 2021 Apr;76(4):472-479.
Van Noorden R. Medicine is plagued by untrustworthy clinical trials. How many studies are faked or flawed? Nature. 2023 Jul;619(7970):454-458. Listen at https://youtu.be/_QLvzCr6nz4?feature=shared
-
On August 1, 2023, Dr Donovan announced the long awaited start of the Evidence Based Hair Fellowship training program. This is an online (virtual) training program for practitioners that wish to develop expertise in hair loss. The program runs Jan 2024 to August 2025 and participants meet once weekly for a three hour period (either on a Wednesday or a Thursday).
In this short recording, Dr Donovan updated listeners on the Evidence Based Hair Fellowship training program.
Interested participants may wish to watch video describing the full program at https://youtu.be/xWBT9sKWU_k?si=6TVCHw3lnNgb2_mk
or download the coarse syllabus at:
https://donovanmedical.com/donovan-hair-academy
-
Alopecia Areata Awareness Month - Recording from Sept 6 2023 Live Public Webinar hosted by Dr Donovan.
Question 1 (starts at 3:50): Is the rate of alopecia areata going up ?
Question 2 (starts at 7:45). What blood tests should be ordered for someone with alopecia areata?
Question 3 (starts at 11:58). Do JAK inhibitors cure alopecia areata?
Question 4 (starts at 15:45). What treatments are possible for eyelash loss?
Question 5 (starts at 17:53). What other medical problems do patients with alopecia areata have?
Question 6 (starts at 20:29). My son is 3 years old and Alopecia. 1 year ago, hair loss started and his hair and eyebrows completely fell out. In the tests , it was determined that his intestinal flora was very disordered and he has lactose and gluten intolerance. There are some doctors who have found that Intestinal Flora Disorder and Leaky Gut Syndrome can cause some autoimmune diseases. I would like to know your thoughts on this subject.
Question 7 (starts at 26:58). Should I ask for a biopsy to prove the diagnosis of alopecia areata?
Question 8 (starts at 29:01). I am a 37 year old female and have alopecia areata. Will I pass this on to my children?
Question 9 (starts at 31:48). Does stress cause alopecia areata? I hear mixed views.
Question 10 (starts at 35:16). My 3 year old developed a small area of alopecia over the summer. What treatment is considered best?
Question 11 (starts at 41:12). Does low vitamin D make alopecia worse?
Question 12 (starts at 43:43). Myalopecia areata is becoming scarring. How is this possible?
Question 13 (starts at 47:13). Do you see loss of efficacy over time of JAK inhibitors and if so what would be the reason
-
STUDIES REFERENCED IN THIS EPISODE
Onamusi T et al (starts at 8:58). Clinical factors and hair care practices influencing outcomes in central centrifugal cicatricial alopecia. Arch Dermatol Res. 2023 May 15. doi: 10.1007/s00403-023-02630-5. Online ahead of print.
Erinolaoluwa F et al (starts at 11:59). Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. JAAD Case Reports Feb 2020
Jackson TK et al (starts at 15:40). Central Centrifugal Cicatricial Alopecia in Males. J Am Acad Dermatol. 2023 Jul 24:S0190-9622(23)02399-X.
Melo RR et al (starts at 21:45). Positive Anagen Pull Test Predicting Lichen Planopilaris Activity. Dermatol Pract Concept. 2023 Jul 1;13(3):e2023140.
Shamloul N et al (starts at 29:14). Incidence and time to development of malignancies arising on the scalp of patients with erosive pustular dermatosis based on sex: A retrospective analysis. J Am Acad Dermatol. 2023 Jun 13;S0190-9622(23)01111-8.
Negbenebor NA et al (starts at 34:45). Nonmelanoma skin cancer in the setting of erosive pustular dermatosis of the scalp: A case series and comment on management implications. Dermatol Ther. 2022 Jul;35(7):e15584. doi: 10.1111/dth.15584. Epub 2022 May 28.
Sarkis A et al (starts at 41:54). Folliculitis Decalvans in women: a retrospective multicenter study of 150 patients. J Eur Acad Dermatol Venereol. 2023 Aug 18.
Vañó-Galván S et al (starts at 43:39). Folliculitis decalvans: a multicentre review of 82 patients. J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1750-7.
-
STUDIES REFERENCE IN THE EPISODE
SWITCHING FROM TOFACITINIB TO BARICITINIB
Kazmi A et al (starts at 12:33). Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response. J Am Acad Dermatol. 2023 Apr 4;S0190-9622(23)00532-7.
RITLECITINIB IN ADOLESCENTS
Hordinsky M et al (starts at 21:31). Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol. 2023 Jul 17.
RISK OF INFECTIONS, CANCER, HEART DISEASE AND BLOOD CLOTS IN AT/AU
George P et al (starts at 36:08). Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database., Dermatol Ther (Heidelb). 2023 Aug; 13(8): 1733–1746.
Schneeweiss MC et al (starts at 37:36). Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. JAMA Dermatol. 2021 Jul 1;157(7):805-816.
MARKERS OF VENOUS THROMBOEMBOLISM IN ALOPECIA AREATA
Sudnik W et al (starts at 57:40) . The role of selectins in alopecia areata. Postepy Dermatol Alergol. 2015 Feb;32(1):27-32.
Shakoei S et al (starts at 58:23). Coagulation status in patients with alopecia areata: a cross-sectional study. Ital J Dermatol Venerol. 2021 Oct;156(5):588-592.
Waśkiel-Burnat A et al (starts at 59:30). Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about? Dermatol Ther (Heidelb). 2023 Aug;13(8):1847-1855.
HABIT REPLACEMENT THERAPY FOR TRICHOTILLOMANIA
Moritz S et al (starts at 1:04:34). Self-Help Habit Replacement in Individuals With Body-Focused Repetitive Behaviors: A Proof-of-Concept Randomized Clinical Trial. JAMA Dermatol. 2023 Jul 19;e232167.
LINK TO VIDEO on HRT DEMONSTRATION https://clinical-neuropsychology.de/habit-replacement-en/#sthash.J6iQiYRi.dpuf
- Laat meer zien
